Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Ascletis Pharma Inc / Equity Capital Markets

<p>Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the first pharmaceutical company to list on Hong Kong Stock Exchange after the amendment of listing rules in April this year, which accepts biotech companies that have not turned a profit. In this insight, we will cover the following topics:</p>
<ul>
<li>The company's product pipeline, particularly Danoprevir (NDA approved) and Ravidasvir (applying for NDA approval)</li>
<li>The HCV market and competing products</li>
<li>Our thoughts on valuation</li>
</ul>
<p>We will provide the valuation analysis and our final view on the deal when the term sheet is available.</p>

Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the first pharmaceutical company to list on Hong Kong Stock Exchange after the amendment of listing rules in April this year, which accepts biotech companies that have not turned a profit. In this insight, we will cover the following topics:

The company's product pipeline, particularly Danoprevir (NDA approved) and Ravidasvir (applying for NDA approval)
The HCV market and competing products
Our thoughts on valuation

We will provide the valuation analysis and our final view on the deal when the term sheet is available.

Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market

China

Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascletis Pharma Inc (1672 HK)

Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market

Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)